The Road toward a Trojan Horse Malaria Vaccine: Chemical Augmentation of Live Sporozoites without Affecting Their Viability
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.6c00575 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Chanel Milène Naar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden2333ZA, The Netherlands. Hauptthemen laut MEDLINE: Sporozoites, Malaria Vaccines, Malaria. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw, Leids Universitair Medisch Centrum, Horizon 2020 European Commission (EC).
Abstract (Originalsprache)
In our effort to design an effective ultralow-dose attenuated whole sporozoite (SPZ) vaccine, we explored the use of chemical adjuvants to increase the immunogenicity of sporozoites. Critical to the potency of attenuated sporozoites is their ability to migrate to and infect the liver. We thus used an in vivo mouse challenge model to compare the effects of external and internal chemical modifications to sporozoites. We loaded sporozoites with CL307 using two strategies: a supramolecular surface modification adjuvant system (SPZ-SAS(CL307)) and a mitochondrial membrane potential system (SPZ-MMP(CL307)). SPZ-SAS(CL307) contained 200 times more CL307 as compared to SPZ-MMP(CL307). However, SPZ-SAS(CL307) could not establish a liver infection after intravenous injection (25 000 sporozoites), suggesting loss of function of the sporozoites. On the contrary, SPZ-MMP(CL307) could establish an equivalent liver infection to the control already at a dose of 5000 sporozoites. When the immunized mice were challenged, SPZ-MMP(CL307) equaled the protective efficacy of control sporozoites. Our findings indicate that the MMP system can be used to chemically augment live cells, such as sporozoites, with adjuvants without negatively affecting their infectivity and protective efficacy in vivo. For malaria, further testing of different types of adjuvants at different concentrations is needed to ultimately develop vaccines with increased potency. However, in essence, this platform provides a proof-of-concept for a Trojan horse adjuvanting or drug loading concept for any whole-cell vaccine or therapy, within the infectious diseases space or beyond in oncological applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden2333ZA, The Netherlands.
- Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden2333ZA, The Netherlands.
ORCID-Profile: Chanel Milène Naar, Fijs W B van Leeuwen
Förderung
- ZonMw
- Leids Universitair Medisch Centrum
- Horizon 2020 European Commission (EC)
Zitieren
APA
Naar, C. M., van Schuijlenburg, R., van Meerbeek, M., Chevalley-Maurel, S., Zigó, L. A., Franke-Fayard, B., van Leeuwen, F. W. B., & Roestenberg, M. (2026). The Road toward a Trojan Horse Malaria Vaccine: Chemical Augmentation of Live Sporozoites without Affecting Their Viability. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00575
Vancouver
Naar CM, van Schuijlenburg R, van Meerbeek M, Chevalley-Maurel S, Zigó LA, Franke-Fayard B, et al. The Road toward a Trojan Horse Malaria Vaccine: Chemical Augmentation of Live Sporozoites without Affecting Their Viability. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00575
BibTeX
@article{Naar2026,
author = {Naar, Chanel Milène and van Schuijlenburg, Roos and van Meerbeek, Maarten and Chevalley-Maurel, Severine and Zigó, Lili A and Franke-Fayard, Blandine and van Leeuwen, Fijs W B and Roestenberg, Meta},
title = {The Road toward a Trojan Horse Malaria Vaccine: Chemical Augmentation of Live Sporozoites without Affecting Their Viability},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c00575}
}
EUVIMED